Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer
About this item
Full title
Author / Creator
Publisher
England: Nature Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
England: Nature Publishing Group
Subjects
More information
Scope and Contents
Contents
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R)
EGFR
substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.
Alternative Titles
Full title
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4665630
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4665630
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/nrclinonc.2013.154
